Dublin, Feb. 20, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Proteomics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics.
Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 28 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 224 of these are profiled in the report with 456 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2016 and are projected to years 2021 and 2026. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
8. Oncoproteomics
9. Neuroproteomics
10. Proteomics Markets
11. Future of Proteomics
12. References
Part II: Companies
11. Companies involved in developing proteomics
For more information about this report visit http://www.researchandmarkets.com/research/n9q3zl/proteomics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Proteomics


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Washington Post Publisher Will Lewis Steps Down After Layoffs
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Instagram Outage Disrupts Thousands of U.S. Users
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



